These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 14739074)

  • 1. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones.
    Smith SA
    Biochimie; 2003 Dec; 85(12):1219-30. PubMed ID: 14739074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones--tools for the research of metabolic syndrome X.
    Komers R; Vrána A
    Physiol Res; 1998; 47(4):215-25. PubMed ID: 9803467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones.
    Arner P
    Trends Endocrinol Metab; 2003 Apr; 14(3):137-45. PubMed ID: 12670740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism.
    Astapova O; Leff T
    Vitam Horm; 2012; 90():143-62. PubMed ID: 23017715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment.
    Takasawa K; Kubota N; Terauchi Y; Kadowaki T
    Endocr J; 2008 Aug; 55(4):767-76. PubMed ID: 18506083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.
    He W; Barak Y; Hevener A; Olson P; Liao D; Le J; Nelson M; Ong E; Olefsky JM; Evans RM
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15712-7. PubMed ID: 14660788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.
    Saraf N; Sharma PK; Mondal SC; Garg VK; Singh AK
    J Pharm Pharmacol; 2012 Feb; 64(2):161-71. PubMed ID: 22221092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mode of action of thiazolidinediones.
    Hauner H
    Diabetes Metab Res Rev; 2002; 18 Suppl 2():S10-5. PubMed ID: 11921433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central role of the adipocyte in insulin resistance.
    Bergman RN; Mittelman SD
    J Basic Clin Physiol Pharmacol; 1998; 9(2-4):205-21. PubMed ID: 10212835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfunctional fat cells, lipotoxicity and type 2 diabetes.
    DeFronzo RA
    Int J Clin Pract Suppl; 2004 Oct; (143):9-21. PubMed ID: 16035392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adiponectin: from adipocyte to skeletal muscle].
    Ferré P
    Ann Endocrinol (Paris); 2004 Feb; 65(1 Suppl):S36-43. PubMed ID: 15163922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
    Mukherjee R; Hoener PA; Jow L; Bilakovics J; Klausing K; Mais DE; Faulkner A; Croston GE; Paterniti JR
    Mol Endocrinol; 2000 Sep; 14(9):1425-33. PubMed ID: 10976920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
    Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
    Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome Proliferator-Activated Receptor γ and Its Role in Adipocyte Homeostasis and Thiazolidinedione-Mediated Insulin Sensitization.
    Wang QA; Zhang F; Jiang L; Ye R; An Y; Shao M; Tao C; Gupta RK; Scherer PE
    Mol Cell Biol; 2018 May; 38(10):. PubMed ID: 29483301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.
    Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M
    Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
    Dubois M; Vantyghem MC; Schoonjans K; Pattou F
    Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and additional vascular effects of thiazolidinediones.
    Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
    Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects.
    Hammarstedt A; Sopasakis VR; Gogg S; Jansson PA; Smith U
    Diabetologia; 2005 Jan; 48(1):96-104. PubMed ID: 15624096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus.
    Heilbronn L; Smith SR; Ravussin E
    Int J Obes Relat Metab Disord; 2004 Dec; 28 Suppl 4():S12-21. PubMed ID: 15592481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.